Our Portfolio
Learn more about our mission-driven companies.
Our Investments
We founded this inflammasome focused company in February 2018 and raised a Series A in February 2020. We have been pleased to work with an excellent management team led by Harlan Weisman and David Barrett. The founders group ended up with approximately 40% of the equity after an initial round of $12mm. Flame completed a $100mm crossover raise in October 2020. The company was sold to Leap Therapeutics in 2023. We have generated a solid return from this investment.
We founded this iNOS inhibition company in November 2023, with a vision to treat breast cancer. Nova’s lead compound is currently being studied in a Phase 1/2 clinical trial and has completed a Phase 1/2 clinical trial in triple negative breast cancer patients. Our stellar team was led by Par S. Hyare and Michael Friedman. In December 2024, Nova was successfully acquired by Galera Therapeutics.
Apovita is developing a first-in-class drug for treating vascular diseases.
